Figures computed from official regulatory filings — .
Analysttarget 490 USD (+19268%)
Ownershipinsiders 11.67% · institutions 8.51% · short 3.1% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Scilex Holding Co only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
15 buys4 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| SCLX Stock Acquisition JV LLC | Other | n/a (No price was disclosed in the filing) | SEC |
| Ji Henrytrack record | SellD (derivative) | $100K | SEC |
| Ji Henrytrack record | BuyD (derivative) | $499.9K | Unusual sizeFirst in 12mo | SEC |
| Ma Stephen Hoi | BuyD (derivative) | $100K | First in 12mo | SEC |
| Scilex Holding Co | Sell | $5.2M | SEC |
| Scilex Holding Co | Sell | $2.8M | SEC |
| Scilex Holding Co | Sell | $4.8M | SEC |
| Followwill Dorman | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ma Stephen Hoi | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chun Jay | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ji Henrytrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Wu Yue Alexander | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SCLX Stock Acquisition JV LLC | Other | n/a (No price was disclosed in the filing) | SEC |
| SCLX Stock Acquisition JV LLC | Other | n/a (No price was disclosed in the filing) | SEC |
| SCLX Stock Acquisition JV LLC | Other | n/a (No price was disclosed in the filing) | SEC |
| SHAH JAISIMtrack record | Buy | $13.8K | conv 54Cluster | SEC |
| Followwill Dorman | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Wu Yue Alexander | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chun Jay | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ji Henrytrack record | Buy | $8.4K | conv 44Cluster | SEC |
| SHAH JAISIMtrack record | Buy | $31.7K | conv 56Cluster | SEC |
| Chun Jay | Buy | $4.8K | conv 59Cluster | SEC |
| Ji Henrytrack record | Buy | $9.7K | conv 51Cluster | SEC |
| Followwill Dorman | Buy | $990 | conv 84ClusterFirst in 12mo | SEC |
| Lemus David | Buy | $1.8K | conv 87ClusterFirst in 12mo | SEC |